Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Queensland Health
Chubb
Cerilliant
Merck
Daiichi Sankyo
Fish and Richardson
Farmers Insurance
Mallinckrodt

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,939,559

« Back to Dashboard

Which drugs does patent 6,939,559 protect, and when does it expire?

Patent 6,939,559 protects OMNARIS and is included in one NDA.

This patent has forty-eight patent family members in thirty-five countries.
Summary for Patent: 6,939,559
Title: Pharmaceutical composition for application to mucosa
Abstract:The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high permeability to the blood at the mucosa. The present invention further provides a pharmaceutical composition for application to the mucosa comprising a hemostatic agent and a medicament. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to permeability and retentivity at the mucosa.
Inventor(s): Nishibe; Yoshihisa (Hino, JP), Kinoshita; Wataru (Hino, JP), Kawabe; Hiroyuki (Tokyo, JP)
Assignee: Teijin Limited (Osaka, JP)
Application Number:09/446,276
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 6,939,559

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,939,559

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10-110887Apr 21, 1998
Japan10-110888Apr 21, 1998
PCT Information
PCT FiledApril 21, 1999PCT Application Number:PCT/JP99/02126
PCT Publication Date:October 28, 1999PCT Publication Number: WO99/53899

Non-Orange Book US Patents Family Members for Patent 6,939,559

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,235,247 Pharmaceutical composition for application to mucosa ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,939,559

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 336986 ➤ Try a Free Trial
Australia 3534399 ➤ Try a Free Trial
Australia 757772 ➤ Try a Free Trial
Bulgaria 104020 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Farmers Insurance
Harvard Business School
Cantor Fitzgerald
Cerilliant
Citi
Fuji
McKinsey
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.